Biomarkers of inflammatory bowel disease activity


Cite item

Full Text

Abstract

The review presents data on calprotectin, lactoferrin, leukocytes labeled with isotope indium 111In, calgranulin C and pyruvate kinase type M2 - highly sensitive biomarkers to assess the severity of intestinal inflammation. Their importance in diagnostics, determination of treatment efficiency, including as predictors of recurrence of ulcerative colitis and Crohn's disease is shown.

About the authors

N A Fadeeva

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

к.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника Moscow, Russia

I A Korneeva

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

клинический ординатор отд-ния лечения воспалительных заболеваний кишечника Moscow, Russia

O V Knyazev

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

д.м.н., зав. отд-нием лечения воспалительных заболеваний кишечника Moscow, Russia

A I Parfenov

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника Moscow, Russia

References

  1. D'Haens G, Feagan B, Colombel J.F, Sandborn W.J, et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031
  2. Lobaton T, Rodriguez-Moranta F, Rodriguez-Alonso L, Guardiola J. Fecal calprotectin in the diagnosis of inflammatory bowel diseases. Gastroenterol Hepatol. 2013;36(6):400-6. doi: 10.1016/j.gastrohep.2012.10.008
  3. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann F.S. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5. doi: 10.1186/1471-230X-12-5
  4. Парфенов А.И., Крумс Л.М. Энтеропатия с потерей белка. Терапевтический архив. 2017;89(2):4-9 doi: 10,17116/terarkh20178924-9
  5. Sherwood R.A. Faecal markers of gastrointestinal inflammation. J Clin Pathol. 2012;65(11):981-5. doi: 10.1136/jclinpath-2012-200901
  6. Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease. Am J Gastroenterol. 2015;110(6):865-72. doi: 10.1038/ajg.2015.30
  7. Burri E, Beglinger C, von Feiten S, Lehmann F.S. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60(2):485-91. doi: 10.1007/s10620-014-3383-0
  8. Labaere D, Smismans A, van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. Unit Eur Gastroenterol J. 2014;2(1):30-7. doi: 10.1177/2050640613518201
  9. Осипенко М.Ф., Ливзан М.А., Скалинская М.И., Лялюкова Е.А. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Терапевтический архив. 2015;87(2):30-3. doi: 10.17116/terarkh201587230-33
  10. Lehmann F.S, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8(1):23-36. doi: 10.1177/1756283X14553384
  11. Molander P, Bjorkesten C, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18(11):2011-7. doi: 10.1002/ibd.22863
  12. Coorevits L, Baert F.J, Vanpoucke H.J. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51(4):825-31. doi: 10.1515/cclm-2012-0386
  13. Pavlidis P, Chedgy F.J, Tibbie. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastoenterol. 2013;48(9):1048-54. doi: 10.3109/00365521.2013.816771
  14. Sithambaram S, Hilmi I, Goh K.L. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test - A Rapid Office Based Assay Test for the Detection of Colorectal Cancer. PLoS One. 2015;10(7):e0131616. doi: 10.1371/journal.pone.0131616
  15. Nielsen H.L, Engberg J, Ejlertsen T, Nielsen H. Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis. Scаnd J Gastroenterol. 2013;48(5):633-5. doi: 10.3109/00365521.2013.775329
  16. Tursi A. Biomarkers in diverticular disease of the colon. Dig Dis. 2012;30(1):12-8. doi: 10.1159/000335695
  17. Schoepfer A.M, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332-41. doi: 10.1097/MIB.0b013e3182810066
  18. Ricanek P, Brackmann S, Perminow G, Lyckander L.G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011;46(9):1081-91. doi: 10.3109/00365521.2011.584897
  19. Roseth A, Kristensen V, Malmstrom G.H, Skar V, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra - individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51(5):548-55. doi: 10.3109/00365521.2015.1117650
  20. De Vos M, Louis E.J, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inlamm Bowel Dis. 2013;19(10):2111-7. doi: 10.1097/MIB.0b013e31829b2a37
  21. Sauter B, Beglinger C, Girardin M, et al. Monitoring disease activity and progression in Crohn's disease. A Swiss perspective on the IBD ahead 'optimised monitoring' recommendations. Digestion. 2014;89(4):299-309. doi: 10.1159/000360283
  22. Naismith G.D, Smith L.A, Barry S.J, et al. A prospective single - centre evaluation of the intra - individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37(6):613-21. doi: 10.1111/apt.12221
  23. Lasson A, Stotzer P.O, Ohman L, Isaksson S, Sapnara M, Strid H. The intra - individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9(1):26-32. doi: 10.1016/j.crohns
  24. Calafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within - day variability of fecal calprotectin levels in patients with active ulcerative colitis: What is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21(5):1072-6. doi: 10.1097/MIB.0000000000000349
  25. Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C, et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high - risk patients. World J Gastroenterol. 2012;18(32):4391-8. doi: 10.3748/wjg.v18.i32.4391
  26. Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease. Unit Eur Gastroenterol J. 2015;3(1):5-10. doi: 10.1177/2050640614558106
  27. Abraham B.P, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012;41(2):483-95. doi: 10.1016/j.gtc.2012.01.007
  28. Menees S.B, Powell C, Kurlander J, Goel A, Chey W.D. A meta - analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. doi: 10.1038/ajg.2015.6
  29. Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry. Dtsch Arztebl Int. 2015;112(8):121-7. doi: 10.3238/arztebl.2015.0121
  30. Mosli M.H, Zou G, Garg S.K, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110(6):802-19. doi: 10.1038/ajg.2015.120

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies